MEIYOUHENG Wins NMPA Approval as World’s First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma

Reuters11-21

MEIYOUHENG Wins NMPA Approval as World's First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma

TOT BIOPHARM International Co. Ltd., in partnership with BioDlink and Lepu Biopharma, has announced the successful regulatory approval and launch of MEIYOUHENG®, the world's first EGFR-targeting ADC drug. The product received marketing approval from China's National Medical Products Administration (NMPA) on October 30, 2025. This milestone marks the first time an antibody-drug conjugate $(ADC)$ fully manufactured by a contract development and manufacturing organization $(CDMO)$ has reached the market in China, highlighting significant progress in the region's biopharmaceutical sector. The achievement underscores the robust collaboration and operational excellence among the involved organizations throughout the development, technology transfer, and manufacturing process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN30878) on November 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585143697?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585143697","market":"us","top_or_hot":-1,"title":"MEIYOUHENG Wins NMPA Approval as World’s First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MEIYOUHENG Wins NMPA Approval as World's First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TOT BIOPHARM International Co. Ltd., in partnership with BioDlink and Lepu Biopharma, has announced the successful regulatory approval and launch of MEIYOUHENG®, the world's first EGFR-targeting ADC drug. The product received marketing approval from China's National Medical Products Administration (NMPA) on October 30, 2025. This milestone marks the first time an antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> fully manufactured by a contract development and manufacturing organization <a href=\"https://laohu8.com/S/CDMO\">$(CDMO)$</a> has reached the market in China, highlighting significant progress in the region's biopharmaceutical sector. The achievement underscores the robust collaboration and operational excellence among the involved organizations throughout the development, technology transfer, and manufacturing process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN30878) on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MEIYOUHENG Wins NMPA Approval as World’s First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMEIYOUHENG Wins NMPA Approval as World’s First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-21 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MEIYOUHENG Wins NMPA Approval as World's First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TOT BIOPHARM International Co. Ltd., in partnership with BioDlink and Lepu Biopharma, has announced the successful regulatory approval and launch of MEIYOUHENG®, the world's first EGFR-targeting ADC drug. The product received marketing approval from China's National Medical Products Administration (NMPA) on October 30, 2025. This milestone marks the first time an antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> fully manufactured by a contract development and manufacturing organization <a href=\"https://laohu8.com/S/CDMO\">$(CDMO)$</a> has reached the market in China, highlighting significant progress in the region's biopharmaceutical sector. The achievement underscores the robust collaboration and operational excellence among the involved organizations throughout the development, technology transfer, and manufacturing process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN30878) on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL4PbFd0:1","article_id":"2585143697","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585143697","pubTimestamp":1763730040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TOT BIOPHARM International Co. Ltd., in partnership with BioDlink and Lepu Biopharma, has announced the successful regulatory approval and launch of MEIYOUHENG, the world's first EGFR-targeting ADC drug. The product received marketing approval from China's National Medical Products Administration  on October 30, 2025. This milestone marks the first time an antibody-drug conjugate  fully manufactured by a contract development and manufacturing organization  has reached the market in China, highlighting significant progress in the region's biopharmaceutical sector. The achievement underscores the robust collaboration and operational excellence among the involved organizations throughout the development, technology transfer, and manufacturing process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01875":"东曜药业-B","02157":"乐普生物-B","BK1574":"生物医药B类股"},"translate_title":"美优恒获得NMPA批准，成为TOT BIOPHARM、BioDlink和乐普生物的全球首个EGFR靶向ADC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":0.9,"01875":0.9},"content_text":"MEIYOUHENG Wins NMPA Approval as World's First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma\n    \n\n        TOT BIOPHARM International Co. Ltd., in partnership with BioDlink and Lepu Biopharma, has announced the successful regulatory approval and launch of MEIYOUHENG®, the world's first EGFR-targeting ADC drug. The product received marketing approval from China's National Medical Products Administration (NMPA) on October 30, 2025. This milestone marks the first time an antibody-drug conjugate $(ADC)$ fully manufactured by a contract development and manufacturing organization $(CDMO)$ has reached the market in China, highlighting significant progress in the region's biopharmaceutical sector. The achievement underscores the robust collaboration and operational excellence among the involved organizations throughout the development, technology transfer, and manufacturing process.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN30878) on November 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585143697","isCrawlerRequest":true}